ABIO
ARCA biopharma Inc

Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement for a single Phase 3 clinical trial. ARCA is also developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically targeted treatment for heart failure and peripheral arterial disease.
Market Cap: 33.4 Million
Primary Exchange: NASDAQ
Website: www.arcabiopharma.com
Shares Outstanding: 14.4 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.574941039973206
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags

Longest drawdown: 2673 trading days
From: 2013-01-31 To: 2022-05-24
Lowest Point:
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|---|---|---|---|---|---|
2015-09-04 | 7.0 | 1.0 | 7.0 | |||
2013-03-05 | 6.0 | 1.0 | 6.0 |